The history of PhinC Development
- Since its creation in 2008 within Genopole, PhinC Development has been built around a strong ambition: to offer innovative solutions for drug development.
- In 2012, with an initial team of 6 employees, we expanded our expertise in the field of MIDD (Model-Informed Drug Development), consolidating our position in scientific innovation and modeling.
- 2014 marked an important milestone with our move to our new offices in Paris Saclay, a dynamic ecosystem dedicated to research and innovation.
- In 2016, PhinC Development continued to grow, reaching 12 employees while expanding its expertise with the integration of PBPK (Physiologically-Based Pharmacokinetic Modeling), a key approach in pharmacokinetic modeling.
- In 2018, our vision extended internationally with the launch of our subsidiary PhinC Modeling in Montreal (Canada). This expansion strengthened our ability to support our global partners in their clinical development challenges.
- In 2020, the team, now consisting of 18 employees, solidified its expertise with a focus on Biologics and innovative approaches to meet the expectations of regulators like the FDA.
- 2022 marked a turning point with the launch of the SimMabs research project, positioning PhinC at the forefront of scientific innovation for monoclonal antibodies.
- In 2025, PhinC Development continues to grow with a team of 26 passionate employees, committed to providing cutting-edge solutions and supporting pharmaceutical companies through all stages of drug candidate development.